1.      Bailey, A.B., Chanderbhan, R., Collazo-Braier, N., Cheeseman, M.A., Twaroski, M.L. The use of structure-activity relationship analysis in the food contact notification program. Regul.Toxicol. Pharmacol. 42 (2005) 225-235.

2.      Jacobson-Kram, D. Contrera, J.F. Genetic toxicity assessment: Employing the best science for human safety evaluation part I: Early screening for potential human mutagens. Toxicol. Sci. 96 (2007)16-20.

3.      Kruhlak, N.L. Contrera, J.F. Benz, R. D., Matthews, E. J. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Advan. in Drug Deliv. 59 (2007) 43-55.

4.      McGovern, T., Jacobson-Kram, D. Regulation of Genotoxic and carcinogenic impurities in drug substances and products. Trends in Anal. Chem. 25 (2006) 790-795.

5.      Valerio, L. G., Arvidson, K. B., Chanderbhan, R. F., Contrera, J. F. Prediction of rodent carcinogenic potential of naturally occurring chemicals in human diet using high-throughput QSAR predictive modeling. Regul. Toxicol. Pharmacol. 222 (2007) 1-16..      Contrera, J.F., Matthews, E.J., Benz, R.D. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 38 (2003) 243-259.

6.      Contrera, J.F., Matthews, E.J., Benz, R.D. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 38 (2003) 243-259.

7.      Contrera, J.F., Hall, L.H., Kier, L.B., MacLaughlin, P. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discov. Technol., 2 (2005) 55-57.

8.      Contrera, J.F., Kruhlak, N.L., Matthews, E. J., Benz, R.D.  Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul. Toxicol. Pharmacol. 49 (2007) 172-182.

9.      Matthews, E. J., Kruhlak, N.L., Benz, R.D., Contrera, J.F. C.A. Marchant, C. Yang. Combined use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows software to achieve high performance, high confidence, mode of action-based predictions of chemical carcinogenesis in rodents. Toxicology Mech. Methods, 18: (2008) 189 - 206.

10.      Contrera, J.F., Matthews, E.J., Kruhlak, N.L., Benz R.D. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL® QSAR software. Regul. Toxicol. Pharmacol. 43 (2005) 313-323.

11.      Contrera, J.F., Matthews, E.J., Kruhlak, N.L., Benz R.D. In silico screening of chemicals for genetic toxicity using MDL-QSAR, non-parametricric discriminant analysis, E-state, connectivity and molecular property descriptors. Toxicology Mech. Methods, 18 (2008) 207- 216.

12.      Contrera, J.F., Matthews, E.J., Kruhlak, N.L., Benz R.D. Estimating the safe starting dose in phase I clinical trials and no observed effect level (NOEL) based on QSAR modeling of the human maximum recommended daily dose (MRDD), Regul Toxicol Pharmacol. 40 (2004) 185-206.

13.      Kruhlak, N. L., Choi, S. S., Contrera, J. F., Weaver, J. L.,Willard, J. M., Hastings, K . L., Sancilio L. F. Development of a phospholipidosis database and predictive quantitative structure activity relationship (QSAR) models. Toxicology Mech. Methods, 18 (2008) 217- 227.